SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo Robert L. Redner, MD

Professor of Medicine

Hematology/Oncology Fellowship Program Director

Email: redner@pitt.edu

Phone: 412-623-3257

Contact
Office: 2.18A Hillman Research Pavilion
5117 Centre Avenue
Pittsburgh, PA 15213
 
Phone: 412-623-3257
Fax: 412-623-7768
E-mail: redner@pitt.edu
Education and Training
Education
BS, Yale College, 1976
M.D., Harvard Medical School, 1980
Training
Internship, Osler Medical Service, The Johns Hopkins Hospital, 1981
Residency, Osler Medical Service, The Johns Hopkins Hospital, 1983
Fellowship, UCLA, 1984
Medical Staff Fellow, Clinical Hematolgy Branch, NHLBI, NIH, 1991
Research Interest
My research interest has been the molecular biology of leukemic transformation and myeloid differentiation. A major focus of my laboratory has been the mechanism underlying differentiation arrest in myeloid leukemia, investigating acute promyelocytic leukemia (APL) as a model system. My group first cloned the NPM-RAR translocation that characterizes the t(5;17) variant of APL, and we have had an active program studying the mechanism by which NPM-RAR generates the leukemic phenotype. I am a physician/scientist in the Division of Hematology/Oncology in the Department of Medicine, and a member of the Cancer Therapeutics Program of the University of Pittsburgh Cancer Institute.
Clinical Interest
Benign and Malignant Hematology, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative diseases, CML
Publications
For my complete bibliography, Click Here.
Selected Publications:
Chattopadhyay A, Abecassis I, Redner RL. NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NF?B and JNK. Leukemia and Lymphoma. Leukemia and Lymphoma. 2015; 56(12): 3401-6.
Johnson DE, Redner RL. An ATRActive future for differentiation therapy in AML. Blood Reviews. 2015; 29(4): 215-280.
Chattopadhyay A, Hood BL, Conrads TP, Redner RL. Extrinsic apoptosis is impeded by direct binding of the APL fusion protein NPM-RAR to TRADD. Molecular Cancer Research. 2014; 12: 1283-1291.
Kropf P, Wang L, Zhang Y, Redner R, Johnson D. Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia. 2010; 24(3): 663-5.
Miranda M, Duan R, Thomas SM, Grandis JR, Redner RL. Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia. 2008; 22: 1624-7.
Miranda MB, Redner RL, Johnson DE. Inhibition of Src family kinases enhances retinoic acid induced gene expression and myeloid differentiation. Molecular Cancer Therapeutics. 2007; 6: 3081-90.
Rego EM, Ruggero D, Tribioli C, Cattoretta G, Kogan S, Render RL. Leukemia with distinct phenotypes in transgenic mice expressing PML/RAR alpha, PLZF/RAR alpha or NPM/RAR alpha. Oncogene. 2006; 25(13): 1974-9.
Redner RL, Chen JD, Rush EA, Li H, Pollock SL. Acute Promyelocytic Leukemia Fusion Protein NPM-RAR Interacts with Co-repressor and Co-activator Proteins and Exhibits both Positive and Negative Transcriptional Properties. Blood. 2000; 95: 2683-2690.
Redner RL, Corey SJ, Rush EA. Differentiation of t(5;17) variant acute promyelocytic leukemic blasts by all-trans retinoic acid. Leukemia. 1997; 11: 1014-1016.
Redner RI, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996; 87(3): 882-886.
Notable Achievements
Visiting Professor, Nippon Medical School, Tokyo, Japan, 1996
Visiting Professor, Jinchi Medical School, Tochigi, Japan, 1996
The Dr. Samuel Dorantes Meza Talk, Mexican Society of Hematology, 2002
Visiting Professor, Asahi General Hospital, Chiba Japan, 2004
Plenary Speaker, Pan-Asia Hematology/Oncology Summit, 2008
Visiting Professor, University of Vermont, 2010
Visiting Professor, West Virginia Medical Centre, 2013
Adrianna M. Salvaggio, MD Dedication to Commitment and Quality Award, Shadyside Hospital, 2013